secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-108315
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio: CORDStrom MAA mid-2026, XPro Phase 3 in 2027; $30M cash as of Oct 14
--------------------------------------------------------------------------------

- CORDStrom Phase 2 in RDEB improves itch/pain; MAA to UK MHRA mid-2026, BLA in US late-2026.
- XPro1595 Phase 2 in early AD halts cognitive decline in biomarker-enriched patients; zero ARIA cases.
- End-of-Phase-2 FDA meeting for XPro in Q1 2026; Phase 3 start planned for 2027.
- Cash $30M as of Oct 14, 2025; market cap ~$50M; ~26.5M shares outstanding.
- CORDStrom has Rare Pediatric Disease and Orphan Drug designations; potential PRV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/0001213900-25-108315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/ea0264915-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer